Álvaro
López Janeiro
Colaborador Clínico
University of Texas MD Anderson Cancer Center
Houston, Estados UnidosUniversity of Texas MD Anderson Cancer Center-ko ikertzaileekin lankidetzan egindako argitalpenak (1)
2023
-
Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial
Nature Medicine, Vol. 29, Núm. 6, pp. 1370-1378